**Brivekimig for Moderate to Severe Hidradenitis Suppurativa** This study is testing a new treatment called *brivekimig* for a skin disease called hidradenitis suppurativa (HS), which causes painful lumps under the skin. The study is *double-blind*, meaning neither the doctors nor the participants know who gets the real treatment or a fake one, called a placebo, to see how well it works. Participants will be in the study for up to 60 weeks if they don't join the long-term part, and up to 52 weeks if they do. The treatment itself lasts about 48 weeks. *Participants need to have HS lesions in at least two body areas and a history of not responding well to antibiotics.* *Some people can't join the study if they have other serious skin problems, infections, or certain health conditions like heart failure or cancer.* *Participants should be aware of possible side effects and need to meet specific health criteria to join.* Key Points:

• The study lasts up to 60 weeks, with 48 weeks of treatment.
• Participants must have had moderate to severe HS for 6 months.
• Certain health conditions may prevent participation.